6533b859fe1ef96bd12b7f47

RESEARCH PRODUCT

Neutralizing human antibodies against CD55 and CD59 targeted to lymphoma cells in vivo potentiate the therapeutic effect of Rituximab

Roberto MarzariPaolo MacorAlberto AmadoriClaudio TripodoSonia ZorzetFrancesco TedescoErich Piovan

subject

biologybusiness.industryImmunologyTherapeutic effectCD59medicine.diseaseLymphomaIn vivoImmunologymedicinebiology.proteinRituximabAntibodybusinessMolecular Biologymedicine.drughttps://doi.org/10.1016/j.molimm.2006.07.152